

PUBLICACIONES GEEIC:

N=166

1. Molina-Infante J, Hirano I. Invited editorial: expanding a narrow perspective on narrow-caliber esophagus in eosinophilic esophagitis. *Aliment Pharmacol Ther* 2014, en prensa.
2. Lucendo AJ, Sanchez-Cazalilla M, Molina-Infante J, Perez-Martinez I, Tenias JM, Barrio J, et al. Transcultural adaptation and validation of the “Adult Eosinophilic Esophagitis Quality of Life Questionnaire” into Spanish. *Rev Esp Enf Dig* 2014;106:386-94.
3. Lucendo AJ, Arias A, Tenías JM, Rodriguez-Sanchez J, Gomez-Torrijos E, Feo-Brito F, Molina-Infante J. Serum IgE-targeted elimination diets for treating eosinophilic esophagitis: things are not what they seem. *Allergy* 2014;69:1567-9.
4. Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L, Cosme A, Gisbert JL, Fernández-Bermejo M, Marcos S, Marín AC, McNicholl AG. Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy. *Dig Dis Sci*. 2014 Sep 19.
5. Molina-Infante J, Arias A, Barrio J, Rodríguez-Sánchez J, Sanchez-Cazalilla M, Lucendo AJ. Four-food group elimination diet for adult eosinophilic esophagitis: a prospective multicenter study. *J Allergy Clin Immunol*. 2014 Aug 27.
6. Molina-Infante J, Javier P. Gisbert. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. *World J Gastroenterol* 2014;10:10338-47.
7. Molina Infante J, Gisbert JP. Bismuth quadruple therapy with Pylera® for H. pylori infection. *Aliment Pharmacol Ther* 2014;40:735-6.
8. Molina Infante J, Katzka DA. Proton pump inhibitor-responsive esophageal eosinophilia. *Current Opin Gastroenterol* 2014;30:428-33.
9. Molina Infante J, Lucendo AJ. Eosinophilic esophagitis: a practical approach to diagnosis and management. *Expert Rev Gastroenterol Hepatol* 2014;16:1-10.
10. Rodríguez-Sánchez J, Gómez Torrijos E, López Viedma B, de la Santa Belda E, Martín Dávila F, García Rodríguez C, Feo Brito F, Olmedo Camacho J, Reales Figueroa P, Molina-Infante J. Efficacy of IgE-targeted vs empiric six-food elimination diets for adult eosinophilic oesophagitis. *Allergy* 2014;69:936-42.
11. Molina Infante J, Gisbert JP, Dellon ES. Distinguishing PPI-responsive esophageal eosinophilia from eosinophilic esophagitis: still a long way to go. *Aliment Pharmacol Ther* 2014;39:1248-9.

12. Molina-Infante J, Santolaria S, Montoro M, Esteve M, Fernandez-Bañares F. Non-celiac gluten sensitivity: a critical review of evidence. *Gastroenterol Hepatol* 2014;37:362-71.
13. Molina-Infante J, Arias A, Vara-Brenes D, Prados-Manzano R, Gonzalez-Cervera J, Alvarado-Arenas M, Lucendo AJ. Propofol administration is safe in adult eosinophilic esophagitis patients sensitized to egg, soy or peanut. *Allergy* 2014
14. Molina Infante J, Calvet X, Gisbert JP. The irony of oral iron: not an underdog for post-GI bleeding anaemia. *Aliment Pharmacol Ther* 2014; 39:550-1.
15. Lucendo AJ, Molina-Infante J. Emerging therapeutic strategies for eosinophilic esophagitis. *Curr Opin Treat Gastroenterol* 2014;12:1-17.
16. Molina Infante J, Gisbert JP. PPI-responsive esophageal eosinophilia: from initial scepticism to consistent prospective data. *Aliment Pharmacol Ther* 2014; 39:229-30.
17. Gisbert JP, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, Castro-Fernández M, Antón R, Sacristán B, Cosme A, Barrio J, Harb Y, Gonzalez-Barcenas M, Fernandez-Bermejo M, Algaba A, Marín AC, McNicholl AG; On behalf of the H. pylori Study Group of the Spanish Gastroenterology Association. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. *DigDisSci* 2014; 59:383-9.
18. McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP; Participant Centres. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. *Gut* 2014; 63:244-9.
19. Vara-Brenes D, Santiago-Cuñer A, Mateos-Rodríguez JM, Fernández-Bermejo M, Molina-Infante J. Aeromonashydrophila colitis as the initial presentation of colon cancer. *GastroenterolHepatol* 2014; 37:270-2. Molina-Infante J, Javier P. Gisbert.
20. Molina Infante J, Gisbert JP. PPI-responsive esophageal eosinophilia: from initial skepticism to consistent prospective data. *AlimentPharmacolTher* 2014; 39:229-30.
21. Molina Infante J, Romano M, Gisbert JP. Reply. *Gastroenterology* 2013;145:1497-8.
22. Molina Infante J, Gisbert JP. Probiotics for Helicobacter pylori infection: not ready for prime time. *Rev Esp Enf Dig* 2013; 105:441-1.

23. Jesus M. Gonzalez-Santiago, Elisa Martin-Noguerol, Gema Vinagre-Rodriguez, Moisés Hernandez-Alonso, Carmen Dueñas-Sadornil, Belen Perez-Gallardo, José M. Mateos-Rodriguez, Miguel Fernandez-Bermejo, Pilar Robledo-Andres, Javier Molina-Infante. Intermittent boluses versus pump continuous infusion for endoscopist-directed propofol administration in colonoscopy. *Rev Esp Enf Dig* 2013;105:378-84.
24. O'Connor JP, Molina-Infante J, Gisbert JP, O'Morain C. Treatment of *Helicobacter pylori* infection 2013. *Helicobacter* 2013; Suppl 1:58-65.
25. Molina Infante J, Gisbert JP. Overcoming antibiotic resistance with *Helicobacter pylori* infection: optimization is the way forward. *Aliment Pharmacol Ther* 2013; 38(2):204-5.
26. Molina Infante J, Katzka DA, Gisbert JP. Review article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis. *Aliment Pharmacol Ther* 2013; 37(12):1157-64.
27. Molina Infante J, Gisbert JP. Seeking esophageal eosinophilia among unselected patients: looking for a needle in a haystack?. *Aliment Pharmacol Ther* 2013; 37(10):1029-30.
28. Javier Molina-Infante, Marco Romano, Miguel Fernandez-Bermejo, Alessandro Federico, Antonietta G. Gravina, Liliana Pozzati, Elena Garcia-Abadia, Gema Vinagre-Rodriguez, Carmen Martinez-Alcala, Moises Hernandez-Alonso, Agnese Miranda, Maria Rosaria Iovene, Carmen Pazos-Pacheco, Javier P. Gisbert. Optimized Non-Bismuth Quadruple Therapies Cure Most Patients with *Helicobacter pylori* Infection in Populations with High Rates of Antibiotic Resistance. *Gastroenterology* 2013; 145(1):121-128.e1.
29. Molina Infante J, Gisbert JP. Quadruple therapy for *Helicobacter pylori*. *Lancet* 2013; 381(9876):1459.
30. Vara-Brenes D, Prados-Manzano R, Molina-Infante J, Mateos-Rodríguez JM, Fernández-Bermejo M. Chemical colitis due to hydrogenperoxide enema. *Gastroenterol Hepatol* 2013; 36(6):439-40.
31. Molina Infante J, Gisbert JP. Actualización de la eficacia de la terapia triple para la infección por *Helicobacter pylori* y de la resistencia a claritromicina en España (2007-2012). *Gastroentero IHepatol* 2013; 36(6):375-81..
32. Gisbert JP, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Domínguez E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanás A, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez J, Calvet X. III Conferencia Española de Consenso sobre la infección por *Helicobacter pylori*. *Gastroenterol Hepatol* 2013; 36(5):340-74.

33. Gisbert JP, Molina Infante J, Marin A, Vinagre-Rodríguez G, Barrio J, McNicholl A. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate *H. pylori* infection. *Scand J Gastroenterol* 2013; 48(6):652-6.
34. Elisa Martín-Noguerol, Jesus M. González-Santiago, Carmen Martínez-Alcalá, Gema Vinagre-Rodríguez, Moisés Hernández-Alonso, Carmen Dueñas-Sadornil, Belén Pérez-Gallardo, José M. Mateos-Rodríguez, Miguel Fernández-Bermejo, Javier Molina-Infante. Split-dose sodium picosulphate/magnesium citrate for morning colonoscopies performed from 2 to 6 hours after fluids intake. *Gastroenterol Hepatol* 2013; 36(4):254-60.
35. Lucendo AJ, Arias A, Molina Infante J, et al. Diagnostic and therapeutic management of eosinophilic oesophagitis in children and adults: results from a spanish registry of clinical practice. *Dig Liv Dis* 2013; 45(7):562-8.
36. Molina-Infante J, Katzka DA. Tissue biomarkers distinguishing GERD from EoE: concerns about the control group. *Am J Gastroenterol* 2013;108:452-3.
37. Molina-Infante J, Santolaria S, Fernandez-Bañares F, Montoro M, Esteve M. Lymphocytic enteropathy, HLA DQ2/DQ8 genotype and wheat-dependent symptoms: non-celiac wheat hypersensitivity or Marsh I celiac disease?. *Am J Gastroenterol* 2013; 108:451.
38. Molina Infante J, Martin Noguerol E, Alvarado Arenas M, Porcel Carreño SL, Jimenez Timon S, Hernandez Arbeiza J. Reply. *J Allergy Clin Immunol* 2013; 131:613-4.
39. Martin-Noguerol E, C. Martinez-Alcala, JM Gonzalez- Santiago, D. Vara- Brenes, Molina-Infante J. Talidomida a dosis altas para la hemorragia digestiva oscura grave en una paciente de alto riesgo trombótico. *Gastroenterol Hepatol* 2013;36:35-8.
40. Molina-Infante J, Ferrando-Lamana L, Vinagre-Rodríguez G. Esophageal hyperkeratosis after proton pump inhibitor therapy in a patient with esophageal eosinophilia. *Gastrointest Endosc* 2013; 77:131-2.
41. Molina Infante J, Martin Noguerol E, Alvarado Arenas M, Porcel Carreño SL, Jiménez Timón S, Hernandez Arbeiza J. Selective elimination diet base don skin testing has suboptimal efficacy for adult eosinophilic esophagitis. *J Allergy ClinImmunol* 2012;130:1200-2.
42. Molina-Infante J, Fernandez-Bermejo M, Mateos-Rodríguez JM. Recurrent rectosigmoid volvulus and fatal peritonitis after percutaneous endoscopic sigmoidostomy. *Endoscopy* 2012;44Suppl 2:E331-2.

43. Molina-Infante J, Dueñas-Sadornil C, Mateos Rodriguez JM, Perez-Gallardo B, Vinagre-Rodriguez G, Hernandez-Alonso M, Fernandez-Bermejo M, Gonzalez-Huix F. Nonanesthesiologist-administered propofol vs. midazolam and propofol, titrated to moderate sedation, for colonoscopy: a randomized controlled trial. *Dig Dis Sci* 2012;57:2385-93.
44. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos Rodriguez JM, Fernandez-Bermejo M, Gisbert JP. Non-bismuth quadruple (concomitant) therapy: empiric and tailored efficacy vs. standard triple therapy for clarithromycin-susceptible *Helicobacter pylori* and vs. sequential therapy for clarithromycin-resistant strains. *Helicobacter* 2012; 17:269-76.
45. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, et al. Fourth-line rescue therapy with rifabutin in patients with three *H. pylori* eradication failures. *Aliment Pharmacol Ther* 2012; 35:941-7.
46. J. Molina Infante, E. Martin Noguero, JM Gonzalez Santiago, C. Martinez Alcalá. Esophageal Dieulafoy lesion resolved through endoscopic band ligation. *Gastroenterol Hepatol* 2012;35:530-1
47. J. Molina Infante, J. Zamorano. Distinguishing EoE from GERD upon PPI-refractoriness: what about PPI-responsive esophageal eosinophilia? *Digestion* 2012; 85:210.
48. J.M. Gonzalez Santiago, J. Molina Infante, L. Crespo Rincón. Abdominal pain and weight loss following adalimumab therapy. *Gastroenterology* 2012; 142:1489-90.
49. J. Molina Infante, J.M Mateos Rodriguez, G Vinagre Rodriguez, E Martin Noguero, JM Gonzalez Santiago. Endoscopic-assisted colopexy and push colostomy in the transverse colon for refractory chronic intestinal pseudo-obstruction. *Surg Laparosc Endosc Percutan Techn* 2011; 21:e322-5.
50. J. Molina Infante, M. Fernandez-Bermejo, J.M. Mateos-Rodriguez. Migrated surgical clip-induced choledocholithiasis. *Endoscopy* 2011 Suppl2; E350-1.
51. J. Molina Infante, G. Vinagre Rodriguez, E. Martin Noguero. A rare cause of dysphagia in an adult patient. *Gastroenterology* 2011; 141:1161-535.
52. J. Molina Infante, M. Fernandez Bermejo, G. Vinagre Rodríguez. Severe gastric ischemia after combined sclerotherapy in a bleeding peptic ulcer. *Endoscopy* 2011; 43Suppl 2:E191.
53. J. Molina Infante, G. Vinagre Rodríguez, E. Martin Noguero, JM González Santiago, C. Martínez Alcalá. Coagulación con argón plasma para la mucosa gástrica heterotópica cervical: una terapia eficaz para la disfagia no respondedora a inhibidores de la bomba de protones. *Gastroenterol Hepatol* 2011;34:372-4.

54. J. Molina Infante, M. Hernández Alonso, G. Vinagre Rodríguez, E. Martín Noguerol. Proton pump inhibitors therapy for esophageal eosinophilia: simply following consensus guidelines. *J Gastroenterol* 2011; 46:712-3.
55. J. Molina Infante, L. Ferrando-Lamana, C. Ripoll, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. *Clin Gastroenterol Hepatol* 2011;9:110-7.
56. J. Molina Infante, JP Gisbert. Levofloxacin in first-line eradication regimens for H pylori: better test antibiotic susceptibility before treating. *Gut* 2011; 60:1605.
57. J. Molina Infante, B. Perez Gallardo. Somatostatin analogues for bleeding gastrointestinal angiodysplasias: when should thalidomide be prescribed?. *Dig Dis Sci* 2011;56:266-7.
58. J. Molina Infante, B. Pérez Gallardo, P. Barros Garcia. Successful pelvic abscess drainage by cecal biopsies in Crohn´s disease. *Gastrointest Endosc* 2011;74:158-9.
59. J. Molina Infante, J.M Mateos Rodríguez. Angiodisplasias. *RevEspEnf* 2010; 102:667.
60. J. Molina Infante, G. Vinagre Rodriguez, E. Martin Noguerol, J.M Gonzalez Santiago, C. Martínez Alcalá. Dieulafo y lesiono verthepectineal line. *Gastroenterol Hepatol* 2010;756-7.
61. J. Molina Infante, M. Fernandez Bermejo, B. Perez Gallardo. Removal of a migrated covered metallic stent through an esophageal stricture with multiple endoloops. *Endoscopy* 2010; Suppl2:E268-9.
62. P. Barquilla-Cordero, M. Chiquero-Palomo, E. Martín-Noguerol, N. Pacheco-Gomez, G. Vinagre-Rodriguez, S.L Moyano-Calvente, J Molina-Infante. Primary pancreatic tuberculosis in an immunocompetent patient: first case report in Spain. *Gastroenterol Hepatol* 2010;33:582-5.
63. J. Molina Infante, J.P Gisbert..One size does not fit all – time to regionalize Helicobacter Pylori eradication? authors reply. *Aliment Pharmacol Ther* 2010;32:507-8.
64. J. Molina Infante, G. Vinagre Rodriguez, E. Martin Noguerol, J. M. Gonzalez Santiago, M. Hernandez Alonso, B. Perez Gallardo, M. Fernandez Bermejo. Duodenal erosions: an uncommon endoscopic marker of celiac disease. *Rev Esp Enferm Dig* 2010;102:443-4.
65. J. Molina Infante, J.P Gisbert. Clarithromycin or levofloxacin in the sequential therapy for H. Pylori? authors reply. *Aliment Pharmacol Ther* 2010;31:1249-50.

66. J. Molina Infante, J. M. Mateos Rodríguez, M. Fernández Bermejo, B. Perez Gallardo, M. Hernandez Alonso. Endoscopic trimming of an embedded distally migrated metallic rectal stent with argon plasma coagulation. *Surg Laparosc Endosc Percutan Tech* 2010;20:e73-5.
67. J. Molina Infante, J. Zamorano. Acid suppressive therapy and eosinophilic esophagitis: friends or foes? *Am J Gastroenterol* 2010; 105:699-700.
68. J. Molina Infante, B. Perez-Gallardo, M. Fernandez-Bermejo, et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2010; 31:1077-84.
69. J. Molina-Infante, L. Ferrando-Lamana. Eosinophilic esophagitis misdiagnosed twice as esophageal candidiasis. *Gastrointest Endosc* 2010;71:395-6.
70. J. Molina-Infante, L. Ferrando-Lamana. Novel endoscopic findings in gastric giardiasis. *Endoscopy* 2009;41Suppl 2:E275.
71. J. Molina-Infante, L. Ferrando-Lamana, Miguel Fernandez-Bermejo, S Porcel-Carreño. Eosinophilic esophagitis in GERD patients: a clinicopathologic diagnosis using proton pump inhibitors. *Am J Gastroenterol* 2009;104:2856-7.
72. J. Molina Infante, B. Pérez Gallardo, M. Hernández Alonso, J.M. Mateos Rodríguez, C. Dueñas Sadornil, M. Fernández Bermejo. Octreotide LAR for severe obscure gastrointestinal haemorrhage in elderly patients with serious comorbidities. *Med Clin (Barc)* 2009; 33(17):667-70.
73. Cortes JR, Rivas MD, Molina-Infante J, Gonzalez-Nuñez MA, Perez-G M, Masa JF, Sanchez JF, Zamorano J. Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. *J Allergy Clin Immunol* 2009;124:607-10.
74. J. Molina Infante, J. Bergua Burgués, N. Fernandez Gonzalez. Diarrhoea caused by colonic relapse of follicular lymphoma. *Brit JHaematol* 2009;146:466.
75. J. Molina Infante, M. Fernández Bermejo, L. Ferrando Lamana, M.S. Jiménez Timón. Esofagitis eosinofílica respondedora a IBP con pHmetría normal. *Revista de la ACAD* vol XXV (65-66); 2009.
76. J. Molina Infante, M. Hernandez Alonso, B. Pérez Gallardo, E. Martin Noguero. Megacolon y megarecto idiopático. *Rev Esp Enf Dig* 2009;101:352-4.
77. Gisbert JP, Bermejo MF, Infante JM, Gallardo BP, Bermejo AB, Rodríguez JM, Andrés PR, García GG. Levofloxacin, Amoxicillin, and Omeprazole as First-line Triple Therapy for *Helicobacter pylori* Eradication. *J Clin Gastroenterol* 2009; 43:384-5.

78. J. Molina Infante, M. Fernandez Bermejo, E. Martin Noguero, B. Pérez Gallardo. Hidatidosis biliar. *Rev Esp Enf Dig* 2009; 101:136-8.
79. J. Molina Infante, M. Hernandez Alonso, B. Pérez Gallardo, E. Martin Noguero. The first Asian case report of eosinophilic esophagitis in an asymptomatic adult: what about a proton pump inhibitor trial?. *J Chin MedAssoc* 2009; 72:166-7.
80. J. Molina Infante, M. Hernández Alonso, E. Martín Noguero, B. Pérez Gallardo, C. Dueñas Sadornil. Alopecia areata como presentación inicial paraneoplásica de un cáncer gástrico. *Gastroenterol Hepatol* 2009; 32:128-30.
81. J. Molina Infante, L. Ferrando Lamana, JM Mateos Rodriguez, B. Perez Gallardo, AB Prieto Bermejo. Overlap of reflux and eosinophilic esophagitis in two patients requiring different therapies: review of the literature. *World J Gastroenterol* 2008; 14:1463-6.
82. J. Molina Infante, M. Hernández Alonso, JM Mateos Rodriguez, C. Dueñas Sadornil, G. Gonzalez García, M. Fernández Bermejo, et al. Ectasia vascular antral gástrica refractaria con extensión al estómago proximal. *Rev Esp Enf Dig* 2009; 101:75-6.
83. J. Molina Infante, A.B. Prieto Bermejo, B. Pérez Gallardo, M. Fernández Bermejo. Pancreatitis aguda tóxica por metformina sin insuficiencia renal. *MedClin (Barc)* 2008; 131:519.
84. J. Molina Infante, M. Hernández Alonso. Hepatobiliary and pancreatic: malignant gallbladder polyp. *J Gastroenterol Hepatol* 2008;23:1622.
85. Coll-Fernández R, Coll R, Pascual T, Sánchez Muñoz-Torrero JF, Sahuquillo JC, Manzano L, Aguilar E, Alcalá-Pedrajas JN, Alvarez LR, García-Díaz AM, Mujal A, Yeste M, Monreal M. Cardiac rehabilitation and outcome in stable out patients with recent myocardial infarction. *Arch Phys Med Rehabil.* 2014 Feb;95(2):322-9. doi:10.1016/j.apmr.2013.09.020. Epub 2013 Oct 9. PubMed PMID: 24121084.
86. Di Micco P, Ruiz-Giménez N, Nieto JA, Aujesky D, del Molino F, Valle R, Barrón M, Maestre A, Monreal M; RIETE investigators. Platelet count and outcome in patients with acute venous thromboembolism. *ThrombHaemost.* 2013 Nov;110(5):1025-34. doi: 10.1160/TH13-04-0352. Epub 2013 Aug 8. PubMed PMID: 23925476.
87. Bertolotti L, Quenet S, Laporte S, Sahuquillo JC, Conget F, Pedrajas JM, Martin M, Casado I, Riera-Mestre A, Monreal M; RIETE Investigators. Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. *Respir Res.* 2013 Jul 18;14:75. doi: 10.1186/1465-9921-14-75. PubMed PMID: 23865769; PubMed Central PMCID: PMC3728047.

88. Nieto JA, Solano R, Trapero Iglesias N, Ruiz-Giménez N, Fernández-Capitán C, Valero B, Tiberio G, Bura-Riviere A, Monreal M; RIETE Investigators. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. *Thromb Res.* 2013 Aug;132(2):175-9. doi:10.1016/j.thromres.2013.06.019. Epub 2013 Jul 9. PubMed PMID: 23849097.
89. Merino J, Mateo-Gallego R, Plana N, Bea AM, Ascaso J, Lahoz C, Aranda JL; Hypertriglyceridemic Registry of Spanish Arteriosclerosis Society. Low-fat dairy products consumption is associated with lower triglyceride concentrations in a Spanish hypertriglyceridemic cohort. *NutrHosp.* 2013 May-Jun;28(3):927-33. doi: 10.3305/nh.2013.28.3.6363. PubMed PMID: 23848121.
90. Lecumberri R, Alfonso A, Jiménez D, Fernández Capitán C, Prandoni P, Wells PS, Vidal G, Barillari G, Monreal M; RIETE investigators. Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. *ThrombHaemost.* 2013 Oct;110(4):834-43. doi: 10.1160/TH13-02-0132. Epub 2013 Jul 11. PubMed PMID: 23846721.
91. Bernaudo D, Coll R, Sánchez Muñoz-Torrero JF, Pascual MT, García-Díaz AM, Alvarez LR, Monreal M; FRENA Investigators. Renal function and short-term outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease. *Atherosclerosis.* 2013 Jul; 229(1):258-62. doi:10.1016/j.atherosclerosis.2013.04.029. Epub 2013 May 9. PubMed PMID: 23714334.
92. Pedragosa A, Merino J, Aranda JL, Galiana J, Godoy D, Panisello JM, Ascaso JF, Civeira F, Masana L, Pedro-Botet J; Registro de HTG de la SEA. Perfil clínico de los pacientes con hipertrigliceridemia muy severa del Registro de Hipertrigliceridemias de la Sociedad Española de Arteriosclerosis. *ClinInvestigArterioscler.* 2013 Jan-Mar; 25(1):8-15. doi: 10.1016/j.arteri.2012.11.001. Epub 2012 Dec 21. Spanish. PubMed PMID: 23522276.
93. Trujillo-Santos J, Schellong S, Falga C, Zorrilla V, Gallego P, Barrón M, Monreal M; RIETE Investigators. Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. *Am J Med.* 2013 May;126(5):425-434.e1. doi: 10.1016/j.amjmed.2012.09.021. Epub 2013 Mar 14. PubMed PMID: 23499331.
94. Otero R, Elías T, Jara L, Trujillo-Santos J, Bertolotti L, Nauffal D, Ruiz-Ruiz J, Blanco-Molina Á, Monreal M; RIETE investigators. Factors associated with elevated pulmonary arterial pressure levels on the echocardiographic assessment in patients with prior pulmonary embolism. *Thromb Res.* 2013 May;131(5):e191-5. doi: 10.1016/j.thromres.2013.01.034. Epub 2013 Mar 7. PubMed PMID: 23466216.

95. Sanclemente C, Yeste M, Suarez C, Coll R, Aguilar E, Sahuquillo JC, Lerma R, Monreal M; FRENA investigators. Predictors of outcome in stable outpatients with peripheral artery disease. *Intern Emerg Med*. 2014 Feb;9(1):69-77. doi: 10.1007/s11739-012-0854-1. Epub 2012 Sep 29. PubMed PMID: 23054402.
96. Soler S, Delgado C, Ballaz A, Cisneros E, Malý R, Babalis D, Monreal M; RIETE Investigators. Unsuspected pulmonary embolism in patients with cancer. *Thromb Res*. 2012 Apr;129 Suppl 1:S16-9. doi: 10.1016/S0049-3848(12)70010-5. PubMed PMID: 22682127.
97. den Exter PL, Gómez V, Jiménez D, Trujillo-Santos J, Muriel A, Huisman MV, Monreal M; Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) Investigators. A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer. *Chest*. 2013 Jan;143(1):138-45. PubMed PMID: 22814859.
98. Nauffal D, Ballester M, Reyes RL, Jiménez D, Otero R, Quintavalla R, Monreal M; RIETE Investigators. Influence of recent immobilization and recent surgery on mortality in patients with pulmonary embolism. *J ThrombHaemost*. 2012 Sep; 10(9):1752-60. doi: 10.1111/j.1538-7836.2012.04829.x. PubMed PMID: 22726525.
99. Aguilar E, García-Díaz AM, Sánchez Muñoz-Torrero JF, Alvarez LR, Piedecausa M, Arnedo G, Monreal M; FRENA Investigators. Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation. *Thromb Res*. 2012 Sep; 130(3):390-5. Epub 2012 May 31. PubMed PMID: 22658293.
100. Riera-Mestre A, Jiménez D, Muriel A, Lobo JL, Moores L, Yusen RD, Casado I, Nauffal D, Oribe M, Monreal M; RIETE investigators. Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism. *J ThrombHaemost*. 2012 May; 10(5):751-9. doi: 10.1111/j.1538-7836.2012.04698.x. PubMed PMID: 22417297.
101. Nuñez MJ, Villalba JC, Cebrián E, Visoná A, Lopez-Jimenez L, Núñez M, Szwebel TA, Luque JM, Jaras MJ, Monreal M; RIETE Investigators. Venous thromboembolism in immobilized patients with dementia. Findings from the RIETE registry. *Thromb Res*. 2012 Aug;130(2):173-7. Epub 2012 Feb 27. PubMed PMID: 22374336.
102. Di Micco P, Fontanella A, Falvo N, Bonithon-Kopp C, Decousus H, Riera-Mestre A, Monreal M; RIETE Investigators. Natural history of patients developing thrombocytopenia while receiving anticoagulant therapy for venous thromboembolism. *IntAngiol*. 2012 Feb; 31(1):92-5. PubMed PMID: 22330631.

103. Gabriel F, Portolés O, Labiós M, Rodríguez C, Cisneros E, Vela J, Nuñez M; RIETE Investigators. Usefulness of thrombophilia testing in venous thromboembolic disease: findings from the RIETE registry. *ClinApplThrombHemost.* 2013 Jan-Feb;19(1):42-7. doi: 10.1177/1076029611436193. Epub 2012 Feb 12. PubMed PMID: 22327823.
104. Tzoran I, Saharov G, Brenner B, Delsart D, Román P, Visoná A, Jiménez D, Monreal M; RIETE Investigators. Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs. *J ThrombHaemost.* 2012 Apr; 10(4):564-71. doi: 10.1111/j.1538-7836.2012.04648.x. PubMed PMID: 22288520.
105. Marchena PJ, Nieto JA, Guil M, García-Bragado F, Rabuñal R, Boccalon H, Trujillo-Santos J, Monreal M; RIETE Investigators. Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism. *ThrombHaemost.* 2012 Jan;107(1):37-43. doi: 10.1160/TH11-06-0423. Epub 2011 Nov 24. Erratum in: *ThrombHaemost.* 2012 Apr; 107(4):801. Multiple investigator names added. PubMed PMID: 22116496.
106. Alvarez LR, Balibrea JM, Suriñach JM, Coll R, Pascual MT, Toril J, López-Jiménez L, Monreal M; FRENA Investigators. Smoking cessation and outcome in stable outpatients with coronary, cerebrovascular, or peripheral artery disease. *Eur J Prev Cardiol.* 2013 Jun;20(3):486-95. doi: 10.1177/1741826711426090. Epub 2011 Oct 3. PubMed PMID: 21968571.
107. Muñoz-Torrero JF, Bounameaux H, Pedrajas JM, Lorenzo A, Rubio S, KearonC,Hernández L, Monreal M; Registro Informatizado de la Enfermedad TromboEmbólica(RIETE) Investigators. Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. *J Vasc Surg.* 2011 Dec; 54(6 Suppl):26S-32S. doi: 10.1016/j.jvs.2011.05.114. Epub 2011 Sep 9. PubMed PMID: 21908150.
108. Lobo JL, Nieto JA, Zorrilla V, Garrido N, Madridano O, Ruiz J, Farge-Bancel D, Tiberio G, Uresandi F, Monreal M; RIETE Investigators. Venous thromboembolism in patients with intracranial haemorrhage. *ThrombHaemost.* 2011 Oct;106(4):750-2. doi: 10.1160/TH11-02-0136. Epub 2011 Sep 8. Erratum in: *Thromb Haemost.* 2011 Dec;106(6):1234. Timiraos, J [added]. PubMed PMID: 21901229.
109. Vega J, Romaní S, Garcipérez FJ, Vicente L, Pacheco N, Zamorano J, Gómez-Barrado JJ, Sánchez Muñoz-Torrero JF. Peripheral arterial disease: efficacy of the oscillometric method. *Rev EspCardiol (Engl Ed).* 2011 Jul;64(7):619-21. doi: 10.1016/j.rec.2010.12.006. Epub 2011 Mar 23. PubMed PMID: 24775652.

110. Vega J, Romaní S, Garcipérez FJ, Vicente L, Pacheco N, Zamorano J, Gómez-Barrado JJ, Sánchez Muñoz-Torrero JF. [Peripheral arterial disease: efficacy of the oscillometric method]. *Rev EspCardiol.* 2011 Jul; 64(7):619-21. doi: 10.1016/j.recesp.2010.10.019. Epub 2011 Mar 23. Spanish. PubMed PMID:21435772.
111. Ascaso JF, Millán J, Mateo-Gallego R, Ruiz A, Suarez-Tembra M, Borrallo RM, Zambon D, Gonzalez-Santos P, Peres-de-Juan M, Ros E; Hypertriglyceridemia Registry of Spanish Arteriosclerosis Society. Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population. *Eur J Intern Med.* 2011 Apr; 22(2):177-81. doi: 10.1016/j.ejim.2010.12.011. Epub 2011 Jan 14. PubMed PMID: 21402249.
112. Trujillo-Santos J, Casas JM, Casado I, Samperiz AL, Quintavalla R, Sahuquillo JC, Monreal M; RIETE Investigators. Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry. *Thromb Res.* 2011 Feb;127Suppl 3:S1-4. doi: 10.1016/S0049-3848(11)00006-5. Erratum in: *Thromb Res.* 2011 Aug;128(2):e1. Casa, José Manuel [corrected to Casas, José Manuel]. PubMed PMID: 21262424.
113. Sanchez Muñoz-Torrero JF, Rivas MD, Costo A, Crespo L, Fraile J, Doncel C, Fernandez Toro JM, Zamorano J. Telmisartan improves insulin resistance in patients with low cytokine levels. *J InvestigMed.* 2011 Mar; 59(3):602-5. doi:10.231/JIM.0b013e31820bf26b. PubMed PMID: 21245772.
114. Bertoletti L, Righini M, Bounameaux H, López-Jiménez L, Tiraferri E, Visona A, Monreal M; RIETE Investigators. Acute venous thromboembolism after non-major orthopaedic surgery or post-traumatic limb immobilisation. Findings from the RIETE registry. *ThrombHaemost.* 2011 Apr;105(4):739-41. doi: 10.1160/TH10-11-0751. Epub 2011 Jan 12. PubMed PMID: 21225101.
115. Muñoz-Torrero JF, Escudero D, Suárez C, Sanclemente C, Pascual MT, Zamorano J, Trujillo-Santos J, Monreal M; Factores de Riesgo y Enfermedad Arterial (FRENA) Investigators. Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y Enfermedad Arterial (FRENA) registry. *J Cardiovasc Pharmacol.* 2011 Jan;57(1):13-9. doi: 10.1097/FJC.0b013e3181fc65e5. PubMed PMID:21164357.
116. Sánchez Muñoz-Torrero JF, Crespo L, Fernández Pereira L, Pereira G, Cámara C, Costo A. [Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age]. *Med Clin (Barc).* 2011 Feb 26;136(5):199-201. doi:10.1016/j.medcli.2010.05.028. Epub 2010 Dec 8. Spanish. PubMed PMID: 21145076.

117. Soto MJ, Grau E, Gadelha T, Palareti G, Bounameaux H, Villalta J, Monreal M; RIETE Investigators. Clinical significance of a negative D-dimer level in patients with confirmed venous thromboembolism. Findings from the RIETE Registry. *J Thromb Haemost.* 2011 Feb;9(2):407-10. doi: 10.1111/j.1538-7836.2010.04143.x. PubMed PMID: 21083645.
118. Mozo, L., D. Rivas, J. Zamorano, and C. Gutiérrez. 1993. Differential expression of IL-4 receptors in human T and B lymphocytes. *J. Immunol.* 1993; 150:4261-4269.
119. Zamorano, J., D. Rivas, A. Gayo, L. Mozo, and C. Gutiérrez. 1995. Soluble but not immobilized anti-IgM antibody inhibits post-activation events leading to T cell-dependent B cell differentiation. *Immunology.* 1995; 85:241-247.
120. Rivas, D., L. Mozo, J. Zamorano, A. Gayo, J.C. Torre, A. Rodríguez, and C. Gutiérrez. 1995. Upregulated expression of IL-4 receptor and increased levels of IL-4 in rheumatoid arthritis patients. *J. Autoimmun.* 8:587-600.
121. Suárez, A., L. Mozo, A. Gayo, J. Zamorano, and C. Gutiérrez. 1997. Requirement of a second signal via protein kinase C or protein kinase A for a maximal expression of CD40 ligand. Involvement of transcriptional and postranscriptional mechanisms. *Eur. J. Immunol.* 1997; 27:2822-2829.
122. Zamorano, J., H.Y. Wang, L.-M. Wang, J.H. Pierce, and A.D. Keegan. 1996. IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. *J. Immunol.* 1996; 157:4926-4934.
123. Wang, H.Y., J. Zamorano, J. Yoerkie, W.E. Paul, and A.D. Keegan. 1997. IL-4-induced tyrosine phosphorylation of IRS-1 is dependent upon expression of JAK-1 in human fibrosarcoma cells. *J. Immunol.* 1997; 158:1037-1040.
124. Wang, D.Z., J. Zamorano, A.D. Keegan, and M.R. Boothby. 1997. HMG-I(Y) phosphorylation status as a nuclear target regulated through the I4R motif of the Interleukin-4 receptor. *J. Biol. Chem.* 1997; 272:25083-25090.
125. Zamorano, J., H.Y. Wang, R.X. Wang, Y. Shi, G.D. Longmore, and A.D. Keegan. 1998. Regulation of cell growth by IL-2: role of STAT5 in protection from apoptosis but not in cell cycle progression. *J. Immunol.* 1998; 160:3502-3512.
126. Keegan A.D. and J. Zamorano. 1998. Regulation of gene expression, growth, and cell survival by IL-4: Contribution of multiple signaling pathways. *Cell Res.* 1998; 8:1-13.
127. Wang, H.Y., J. Zamorano, and A.D. Keegan. 1998. A role for the Insulin-Interleukin (IL)-4 receptor motif of the IL-4Ra in regulating activation of the insulin receptor substrate 2 and signal transducer and activator of transcription-6 pathways. Analysis by mutagenesis. *J. Biol. Chem.* 1998; 273:9898-9905.

128. Zamorano, J., and A.D. Keegan. 1998. Regulation of apoptosis by tyrosine-containing domains of the IL-4Ra: Y497 and Y713, but not the STAT6-docking tyrosines, signal protection from apoptosis. *J. Immunol.* 1998; 161:859-867.
129. Mozo L, A. Gayo, A. Suarez, D. Rivas, J. Zamorano, and C Gutierrez. 1998. Glucocorticoids inhibit IL-4 and mitogen-induced IL-4Ra chain expression by different post-transcriptional mechanisms. *J. Allergy Clin Immunol.* 1999; 102:968-76.
130. Wang H.Y., C.P. Shelburne, J. Zamorano, A.E. Kelly, and A.D. Keegan. 1999. Effects of an allergy-associated mutation in the huIL-4Ra (Q576R) on huIL-4-induced signal transduction. *J. Immunol.* 1999; 162:4385-4389.
131. Nelms, K., J.J. Ryan, J. Zamorano, A.D. Keegan, and W.E. Paul. 1999. The IL-4 receptor: signaling mechanisms and biological functions. *Annu. Rev. Immunol.* 1999; 17:701-738.
132. Zamorano, J., A.E. Kelly, J. Austrian, H.Y. Wang, and A.D. Keegan. 2001. Costimulation of resting B lymphocytes alters the IL-4-activated IRS-2 pathway in a STAT6 independent manner: implications for survival and proliferation. *Cell Res.* 2001; 11:44-54.
133. Zamorano, J., A. L. Mora, M. Boothby, and A.D. Keegan. 2001. NF- κ B activation plays an important role in the IL-4-induced protection from apoptosis. *Int Immunol.* 2001; 13:1479-1487.
134. Perez-G M., M. Melo, A.D. Keegan, and J. Zamorano. 2002. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. *J. Immunol.* 2002; 168:1428-1434.
135. J. Zamorano, M.D. Rivas, and M. Perez-G. 2003. Interleukin-4: A multifunctional cytokine. *Inmunología* 2003; 22:215-224.
136. Zamorano, J., M.D. Rivas, A. Garcia-Trinidad, C.K. Qu, and A.D. Keegan. 2003. Phosphatidylcholine-specific phospholipase C activity is necessary for the activation of STAT6. *J. Immunol.* 2003; 171:4203-4209.
137. Zamorano J., M.D. Rivas, F. Setien, and M. Perez-G. 2005. Proteolytic regulation of activated STAT6 by calpains. *J. Immunol.* 2005; 174:2843-2848.
138. Sanchez de Cos, J., D. Masjoans, M.A. Sojo, J. Zamorano, C. Disdier, and M. C. Perez. 2007. Metástasis encefálicas silentes en la estadificación inicial del cáncer de pulmón. Evaluación mediante tomografía computarizada y resonancia magnética. *Arch Bronconeumol.* 2007; 43:386-391.

139. Cortes J.R., M. Perez-G, M.D. Rivas, and J. Zamorano. 2007. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. *J Immunol.* 2007; 179:3881-3887. IF 6.0 Q1
140. Perez-G, M., J.R. Cortes, M.D. Rivas, F. Masa, and J. Zamorano. 2008. Treatment of cells with n-alpha-tosyl-L-phenylalanine-chloromethyl ketone induces the proteolytic loss of STAT6 transcription factor. *Mol Immunol.* 2008; 45:3896-3901. IF 3.5 Q2
141. Masa J.F., J. Corral., J. Teran.,M.J. Martin, C. Disdier, M. Rubio, M. Mota, J. Zamorano, and J.M. Montserrat. 2009. Apnoeic and obstructive non-apnoeic sleep respiratory events. *Eur Respir J.* 2009; 34:156-161. IF 5.9 D1
142. Cortes, J.R., M.D. Rivas, J. Molina-Infante, M.A. Gonzalez-Nuñez, M. erez-G, J.F. Masa, J.F. Sanchez, and J. Zamorano. 2009. Omeprazole inhibits IL-4 and IL-13 signaling STAT6 activation and reduces lung inflammation in murine asthma. *J Allergy Clin Immunol.* 2009; 124:607-610, 610e1. IF 9.5 D1
143. Molina-Infante, J., and J. Zamorano. 2010. Acid-Suppressive Therapy and Eosinophilic Esophagitis: Friends or Foes ? *Am J Gastroenterol* 2010; 105:699-700. IF 6.8 D1
144. Vega, J., S. Romani, F.J. Garciperez, J. Zamorano, and J.F. Sanchez. 2010.
145. Ankle-brachial index measurement in primary care setting. *South Med. J.* 2010; 103:590. IF 0.76 Q3
146. J.F. Sanchez, P. Barquilla, R. Velasco, C. Fernandez, N. Pacheco, L. Vicente, J.L. Chicon, S. Trejo. J. Zamorano, and A. Lorenzo. 2010. Adverse drug reactions in internal medicine units, and risk factors associated. *Eur. J. Clin. Pharmacol.* 2010; 66:1257-1264. IF 3.03 Q2
147. Sanchez Muñoz-torrero, J.F., L. Crespo, J.M. Ramirez, F. Álvarez, J. Luengo, J. Mateos, N.R. Robles, J. Zamorano, and A. Costo. 2010. Efectos de un consejo nutricional simple en pacientes de alto riesgo vascular. *Clin Invest Arterioscl.* 2011; 23(1):8-14.
148. Masa, J.F., M.T. Gonzalez, R. Pereira, M. Mota, J.A. Riesco, J. Corral, J. Zamorano, M. Rubio, J. Teran, and R. Farre. 2010. Validity of spirometry performed on-line. *Eur. Respir. J.* 2011; 37:911-918. IF 5.9 D1

149. Sanchez Muñoz-Torrero, J.F., D. Escudero, C. Suarez, C. Sanclemente, M.T. Pascual, J. Zamorano, M. Monreal and the FRENA Investigators. 2011. Concomitant use of proton-pump inhibitors and clopidogrel in patients with coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry. *J Cardiovasc Pharm* 2011; 57:13-19. IF 2.4 Q2
150. Sanchez Muñoz-Torrero, J.F., M.D. Rivas, A. Costo, L. Crespo, J. Fraile, C. Doncel, J.M. Fernandez-Toro, and J. Zamorano. 2011. Telmisartan improves insulin resistance in patients with low cytokine levels. *J. Invest. Med.* 2011; 59:602-605. IF 1.54 Q2
151. Vega J., S. Romani, F.J. Garciperez, L. Vicente, N. Pacheco, J. Zamorano, J.J. Gomez-Barrado, and J.F. Sanchez. 2011. Peripheral arterial disease: Efficacy of the oscillometric method. *Rev Esp Cardiol.* 2011; 64:619-621. IF 2.16 Q2
152. Masa JF, Corral J, Pereira R, Duran-Cantolla J, Cabello M, Hernández-Blasco L, Monasterio C, Alonso A, Chiner E, Zamorano J, Aizpuru F, Montserrat JM; SpanishSleep Network. 2011. Therapeutic decision-making for sleep apnea and hypopnea syndrome using home respiratory polygraphy: a large multicentric study. *Am J Resp Crit Care Med.* 2011; 184(8):964-71. IF 10.19 D1
153. Muñoz-Torrero JF, Zamorano J. 2011. Vertebral fractures. *N Engl J Med.* 2011; 365(7):673-4. IF 53.5 D1
154. Molina-Infante, J, J. Zamorano, M.D. Rivas, and M. Fernandez-Bermejo. 2011. Proton pump inhibitors therapy for eosinophilic esophagitis. *J Aller Ther* 2011; S8(002):1-4.
155. Molina-Infante, J, and J. Zamorano. 2012. Distinguishing eosinophilic esophagitis from gastroesophageal reflux disease upon PPI refractoriness: What about PPI-responsive esophageal eosinophilia?. *Digestion* 2012; 85:210. IF 2.15 Q3
156. Sanchez Muñoz-Torrero, J.F., M.D. Rivas, R. Alonso, L. Crespo, A. Costo, M. Roman, C. Martin, and J. Zamorano. 2012. Influence of lipoprotein (a) on inflammatory biomarkers in metabolic syndrome. *South Med. J.* 2012; 105:339-343. IF 0.76 Q3.
157. Masa J. F., J. Corral, J. Gomez de Terreros, J. Duran-Cantolla, M. Cabello, L. Hernández-Blasco, C. Monasterio, A. Alonso, E. Chiner, F. Aizpuru, J. Zamorano, R. Cano, J.M. Montserrat; Collaborating group, Garcia-Ledesma E, Pereira R, Cancelo L, Martinez A, Sacristan L, Salord N, Carrera M, Sancho-Chust JN, Embid C. 2013. Significance of including a surrogate arousal for sleep apnea-hypopnea syndrome diagnosis by respiratory polygraphy. *Sleep.* 2013 Feb 1; 36(2):249-57. doi: 10.5665/sleep.2384. PMID: 23372273

158. Cabrera C. M. , J. M. Urra, A. Carreño A, and J. Zamorano. 2013 Differential expression of CD30 on CD3 T-lymphocytes in patients with systemic lupus erythematosus. *Scand J Immunol.* 2013 Sep; 78(3):306-12. doi: 10.1111/sji.12088. PMID 23790231.
159. Molina-Infante, J., MD Rivas, G Vinagre, M Hernandez, JM Mateos, C Dueñas, B Perez, R Bañares, J Zamorano. Remission in Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. *Gastroenterology* 2013; 144 (Suppl 1): S-484.
160. Masa JF, Corral J, Sanchez de Cos J, Duran-Cantolla J, Cabello M, Hernández-Blasco L, Monasterio C, Alonso A, Chiner E, Aizpuru F, Vázquez-Polo FJ, Zamorano J, Montserrat JM; Collaborating group; Garcia-Ledesma E, Pereira R, Cancelo L, Martínez A, Sacristan L, Salord N, Carrera M, Sancho-Chust JN, Negrín MA, Embid C. Effectiveness of three sleep apnea management alternatives. *Sleep.* 2013 Dec 1; 36(12):1799-807. doi: 10.5665/sleep.3204. PMID: 24293754
161. Urra, J. M., Feo Brito, F., Carrasco, P., De la Roca, F., Zamorano, J. Allergen stimulation induces simultaneous production of type 2 helper T cells and regulatory cytokines in patients with pollen allergy. *J Invest Allergol Clin Immunol*, 2013; 23:54-55. PMID: 23653976
162. Molina-Infante, J., Rivas, M. D., Hernandez-Alonso, M., Vinagre-Rodriguez, G., Mateos-Rodriguez, J. M., Duenas-Sadornil, C., Perez-Gallardo, B., Ferrando-Lamana, L., Fernandez-Gonzalez, N., Bañares, R., Zamorano, J. Proton pump inhibitor responsive oesophageal eosinophilia correlates with down regulation of eotaxin-3 and Th2 cytokines overexpression. *Aliment Pharmacol Ther.* 2014, doi:10.1111/apt.12914. PMID: 25112708
163. Sanchez Munoz-Torrero J. F., Lorenzo-Hernandez A., Trujillo-Santos J., Fernandez-Capitan C., Zamorano J., Monreal M. Natural history of venous thromboembolism in patients from the Mediterranean region. A systematic review *Rev Clin Esp.* 2014; 184-191. PMID 24564993
164. Sanchez Munoz-Torrero J. F., Rivas M. D., Zamorano J., Alonso R., Joya-Vazquez P., Padro T., Mata P. rs1801275 Interleukin-4 receptor alpha polymorphism in familial hypercholesterolemia. *J Clin Lipidol.* 2014; 8:418-422. PMID: 25110223.
165. Molina-Infante J, Rodriguez-Sanchez J, Martinek J, van Rhijn BD, Krajciova J, Rivas MD, Barrio J, Moawad FJ, Martinez-Alcalá C, Bredenoord AJ, Zamorano J, Dellon ES. Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. *Am J Gastroenterol.* 2015 Nov; 110(11):1567-75. doi: 10.1038/ajg.2015.314. Epub 2015 Sep 29. PMID: 26416193.